- Home
- CCCC vs SOR Comparison
CCCC vs SOR Comparison
Compare CCCC & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- SOR
- Stock Information
- Founded
- CCCC 2015
- SOR 1968
- Country
- CCCC United States
- SOR United States
- Employees
- CCCC N/A
- SOR N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- CCCC Health Care
- SOR Finance
- Exchange
- CCCC Nasdaq
- SOR Nasdaq
- Market Cap
- CCCC 244.9M
- SOR 345.6M
- IPO Year
- CCCC 2020
- SOR N/A
- Fundamental
- Price
- CCCC $3.64
- SOR $42.79
- Analyst Decision
- CCCC Buy
- SOR
- Analyst Count
- CCCC 6
- SOR 0
- Target Price
- CCCC $10.67
- SOR N/A
- AVG Volume (30 Days)
- CCCC 1.9M
- SOR 16.2K
- Earning Date
- CCCC 02-20-2025
- SOR 01-01-0001
- Dividend Yield
- CCCC N/A
- SOR 7.24%
- EPS Growth
- CCCC N/A
- SOR N/A
- EPS
- CCCC N/A
- SOR 6.50
- Revenue
- CCCC $33,668,000.00
- SOR N/A
- Revenue This Year
- CCCC $75.79
- SOR N/A
- Revenue Next Year
- CCCC N/A
- SOR N/A
- P/E Ratio
- CCCC N/A
- SOR $6.41
- Revenue Growth
- CCCC 65.45
- SOR N/A
- 52 Week Low
- CCCC $3.25
- SOR $36.41
- 52 Week High
- CCCC $11.88
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- CCCC 41.72
- SOR 47.89
- Support Level
- CCCC $3.25
- SOR $41.87
- Resistance Level
- CCCC $3.84
- SOR $42.56
- Average True Range (ATR)
- CCCC 0.20
- SOR 0.79
- MACD
- CCCC -0.01
- SOR 0.09
- Stochastic Oscillator
- CCCC 29.49
- SOR 66.46
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.